What is it about?
The objective of this study was to characterize rituximab pharmacokinetics in patients with diffuse large B-cell lymphoma. The findings indicates that time-changes in clearance could serve as a predictive marker of response to rituximab.
Featured Image
Why is it important?
This is the first study in aggressive non-Hodgkin lymphoma to demonstrate target-mediated drug disposition of rituximab. Our study is the first to show the association of disease progression with the rate of rituximab clearance decay. The rate of rituximab clearance decay may serve as one of predictive markers of rituximab response.
Perspectives
Our report demonstrates the rationale for studies evaluating higher doses of rituximab in selected patients.
Barbara Jezeršek Novaković
Read the Original
This page is a summary of: Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome, British Journal of Clinical Pharmacology, March 2017, Wiley,
DOI: 10.1111/bcp.13271.
You can read the full text:
Contributors
The following have contributed to this page
